David Chang, M.D., Ph.D. is the CEO of Allogene Therapeutics, a company he co-founded in June 2018. With a strong background in biomedical sciences, he possesses both an M.D. and a Ph.D., which reflects his deep understanding of the life...

David Chang, M.D., Ph.D. is the CEO of Allogene Therapeutics, a company he co-founded in June 2018. With a strong background in biomedical sciences, he possesses both an M.D. and a Ph.D., which reflects his deep understanding of the life sciences and medicine. Under his leadership, Allogene has made significant strides in developing innovative cancer therapies using CAR T-cell technology. In fact, Dr. Chang was instrumental in achieving key corporate goals, including the initiation of clinical trials and the successful completion of a public offering. His compensation reflects this success; in 2023, he earned over $1.4 million, primarily from his salary and performance bonuses. However, he focuses on driving company performance rather than accumulating wealth through stock options, as he has not reported any vested stock since becoming CEO. David Chang’s previous experience also includes serving as the Chief Medical Officer of Kite Pharma, where he played a key role in developing their CAR T therapies. His strategical perspectives stem from years in the industry, making him a valuable asset in the fast-evolving field of therapeutic development.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Allogene Therapeutics CEOs

A

David Chang, M.D., Ph.D.

Founder and Ex-CEO of Allogene Therapeutics

Education

M.D. and Ph.D.

Field of Expertise

Healthcare & Life Sciences - Biomedical

Sector of Economy

Healthcare

Born

January 1, 1978 - 47 years ago

CEO of Allogene Therapeutics for

4 years 10 months (Dec 2018 - Oct 2023)

Previous Experience

Chief Executive Officer of Allogene Therapeutics, Inc.

Rivals

Competitors/colleagues of David Chang, M.D., Ph.D.

Holdings

See how much did David Chang, M.D., Ph.D. make over time.

As of now, Dr. Chang holds over 5 million shares in Allogene Therapeutics, which is about 4.1% of the company. His shares come from a mix of personal investments and stock options. Notably, in prior years, his stock options were...

As of now, Dr. Chang holds over 5 million shares in Allogene Therapeutics, which is about 4.1% of the company. His shares come from a mix of personal investments and stock options. Notably, in prior years, his stock options were valued at upwards of $57 million, showcasing how his involvement in the company has a direct impact on his wealth. However, all of his stock is subject to vesting restrictions, meaning he is aligned with the company’s long-term success. While he had a significant number of options granted in earlier years, like 568,600 in 2020, he has shifted focus to performance bonuses, which have also fluctuated based on the company's achievements.

Total Stock Sold

$1.53M

ALLO

$1.53M

157,167 ALLO shares

What if they kept their stock?

If David Chang, M.D., Ph.D. didn't sell their stock, today they would have:
Extra ALLO157,167 shares worth $3.57M.
This is 133.69% and $2.04M more than what they got when they sold the stock.

Insider Trading

See recent insider trades of David Chang, M.D., Ph.D..

ALLO

$91.47K

ALLO at $1.96/share

Mar 14, 2025

Sale

ALLO

$77.29K

ALLO at $1.68/share

Feb 3, 2025

Sale

ALLO

552,174 shares

ALLO

Jan 24, 2025

Received

ALLO

$1.00M

ALLO at $2.90/share

May 16, 2024

Received

ALLO

317,800 shares

ALLO

Jan 25, 2024

Received

ALLO

1,924,464 shares

ALLO

Mar 22, 2023

Received

ALLO

$180.88K

ALLO at $7.65/share

Mar 15, 2022

Sale

ALLO

80,452 shares

ALLO

Mar 26, 2021

Received

ALLO

$791.27K

ALLO at $38.57/share

Mar 15, 2021

Sale

ALLO

411,556 shares

ALLO

Mar 26, 2021

Charity

Compensation History

See how much did David Chang, M.D., Ph.D. make over time.

In 2023, Dr. Chang received a total compensation package of $1,496,188. This includes a base salary of $724,000 and a performance-based bonus of $270,595. The bonus is based on achieving corporate goals, with a score of 57.5%. His compensation structure aligns executive pay with company performance, reflecting a pay-for-performance philosophy. This means Dr. Chang is rewarded based on the success of Allogene Therapeutics, which is critical in the biotechnology sector where meeting developmental milestones can lead to significant increases in stock value and market presence. In the previous year, 2022, his total compensation was slightly lower at around $1,100,480, indicating growth in both the company and his role as CEO. In general, his pay is snapped within the context of performance metrics that focus on clinical and operational achievements.

Year

2023

Total Compensation

$994.60K

Salary

$724.00K

Board Justification

The compensation philosophy emphasizes a pay-for-performance structure, aligning executive compensation with company performance and retention strategies.

Bonus

$270.60K

Board Justification

The annual performance-based cash incentive for 2023 was based on the achievement of corporate goals, which were scored at 57.5%.

Other

$0.00

Board Justification

No additional compensation was reported outside of salary, bonus, and stock options.

Restricted Stock

$0.00(0 N/A)

Board Justification

No stock was reported as vested in 2023; the focus is on the total compensation excluding stock grants.

Performance Metrics

The performance metrics for 2023 included corporate goals related to clinical and operational objectives.

Other Allogene Therapeutics CEOs

Here are other CEOs of Allogene Therapeutics

Geoffrey Parker

CEO of Allogene Therapeutics

October 2023 - Present